A Healthcare Analytics Company

Custom AI Agents for Biotech and Pharmaceutical Companies … RAG enhanced and validated!

About Us

OBiS is a New York City-based company that was founded in 2002 by Rick Beasley, former Director of Oncology Market Research at Bristol-Myers Squibb. Initially, OBiS developed competitive intelligence tools for oncology sales forces and medical science liaison specialists. Over time, we have expanded our offerings to include clinical trial recruitment profiling tools, key opinion leader identification (KOL), and business forecasting services. In July 2020, OBiS opened a subsidiary office in France to develop its analytical capabilities and better serve European markets. Today, OBiS is known for having one of the most comprehensive business-focused knowledge bases of new and existing medicines, which allows us to offer clients fast, accurate, and insightful analytical products and services with broad coverage across all human disease areas.

Products and Services

Business Development

- Competitive analysis
- Company valuations
- Forecasting

Clinical Development

- Protocol feasibility analysis
- Patient recruitment analytics
- Site identification and profiling

Data Services

- ChatGPT AI applications
- Custom client data integration
- Specialized analytical tools

Finance

- Portfolio planning services
- Risk assessments
- Therapeutic index funds

Marketing

- Primary and secondary market research
- Return on investment (ROI) analysis
- Key opinion leader (KOL) identification

Exploratory Projects

Exploratory projects are used by OBiS to help identify new business opportunities.  Generally the projects have an element of social good, and often are student led.

Biopharma Career Exploration (BCE)

The BCE is a pilot program designed to give students the opportunity to explore in depth a specific sector of the biotechnology or pharmaceutical industry in terms of the career opportunities.  The program was recently launched based on engineering careers with contract manufacturing organizations (CMO) in the biopharma industry.

Personalized Medicine (i.e. Pharmacogenetics)

Personalized medicine, also referred to as pharmacogenetics, involves the selection of medicine based on an individual’s genetic profile. Today’s medicine can have different effects in different people both in terms of the effectiveness of the drug and the side effects.  The current approach to managing these differences is often simply by trial and error which can be costly and have severe patient health consequences.  In the future, there will be the opportunity to perform a test of the patient’s genetic profile before prescribing the medicine thus prescribing the optimum treatment.  In fact, the NIH predicts in the future ones complete genetic profile can be stored on a smart phone (2030 bold prediction #8).  In 1990, the first human genome was completely sequenced.  Since that time, the costs has dropped precipitately from $100,000 in 2001 to $1,000 in 2020 [source: NIH Genome Initiative].  There are even some companies expecting the cost to drop to $100, making it as common as a blood test.

This OBiS exploratory project is based on a simple premise that if there are patient and financial benefits, why not find ways to implement personalized medicine sooner.  There are many other considerations such as ethical and privacy, that need to be addressed to result in the successful advancement of personalized medicine that are intended to be addressed as part of the project.

France-Africa Clinical Development

Clinical trials are needed to test the safety and effectiveness of new medicines.  As new medicines are becoming more targeted and specialized, it is becoming more difficult to find patients to participate in the clinical trials.  Clinical trials provide a “win-win-win” opportunity for patients, medicines developers and institutions (hospitals and clinics) conducting the trials.  There are many nations in Africa where patients and health care institutions could benefit from increasing the level of clinical testing.  Over 140 million people in Africa speak French across 34 nations, thus, France is in a leadership position to facilitate the development of clinical testing in Africa.  Despite the potential for success there are many obstacles and challenges that must be overcome which must be done with a strong ethical framework and complete respect for patient benefit and well-being.

Turbo-charging the French Biotechnology Industry

Throughout history, France has play a pivotal role in the advancement of medicine.  Globally, the biotechnology industry has become extremely competitive.  For France to maintain its competitive edge, it needs to proactively find ways to encourage both interest and investment.  The purpose of this Exploratory Project is to identify new innovate ways in which France can grow its biotechnology industry.

Contact Us

contactus@obis.com

https://www.linkedin.com/company/obis-inc

United States Headquarters

OBiS, Inc.

12 West 32nd Street – 5th Floor

New York, NY 10017

Tel: (1) 646 988 4556

French Subsidiary

OBiS SAS

14 rue Despourrins

64 400 Oloron-Saint-Marie

Tel: (33) 06 31 00 68 25